

Cysteinyl Leukotrienes Mediate Histamine Hypersensitivity Ex Vivo by Increasing Histamine Receptor Numbers

Gwenda Pynaert,^{1,2} Johan Grooten,¹
Sander J. H. van Deventer,² and Maikel P. Peppelenbosch^{1,2}

¹Department for Molecular Biology, Flanders Interuniversity Institute for Biotechnology and University of Ghent, Ghent, Belgium

²Laboratory for Experimental Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands

Accepted September 7, 1999.

Abstract

Background: Hyperresponsiveness to histamine is a key feature of a variety of pathological conditions, including bronchial asthma, food allergy, colitis ulcerosa, and topical allergic disorders. Cells isolated from hyper-responsive individuals do not display exaggerated histamine responses ex vivo and thus the molecular mechanisms underlying histamine responsiveness remain obscure. Importantly, several in vivo observations implicate cysteinyl leukotrienes as possible mediators of increased histamine responses. We decided to investigate whether cysteinyl leukotrienes enhance the cellular reaction to histamine in cell types involved in pathological and immunological histamine hyperresponsiveness, as this might provide an in vitro system for studying histamine responsiveness and could shed light on the underlying molecular mechanisms.

Materials and Methods: Histamine responsiveness was determined by measuring histamine-induced prostaglandin E₂ production. Scatchard analysis was performed to determine the number of histamine H₁ receptors. Mouse macrophages, primary isolated human peripheral blood monocytes, and human umbilical smooth muscle cells were investigated before and after cysteinyl leukotriene stimulation.

Results: In all three cell types tested, cysteinyl leukotrienes instantaneously enhanced histamine-induced prostaglandin E₂ production. This increase in prostaglandin E₂ production coincided with the immediate and transient appearance of additional H₁ receptors on the plasma membrane.

Conclusions: Cysteinyl leukotrienes prime histamine responses by recruiting additional histamine receptors in immunologically relevant cell types in vitro.

Introduction

Histamine, which is produced by decarboxylation of the amino acid L-histidine (1), is found in most tissues, mainly in the granules of mast cells, although numerous other cell types are capable of histamine synthesis as well (2).

Histamine controls a large number of physiological functions by stimulating specific receptors on target cells. On the basis of their sensitivity to specific antagonists and agonists, three types of receptors for histamine have been characterized and named: the histamine receptor H₁, H₂, and H₃ (3). In general, activation of the H₃ receptor is associated with auto-inhibition of histamine production and release, stimulation of the H₂ receptor is associated with gastric acid release, and the H₁ receptor is implicated in inflammation, mediating, for

Address correspondence and reprint requests to Dr. Maikel P. Peppelenbosch, Laboratory for Experimental Internal Medicine, G2-130 Academic Medical Centre, Meibergdreef 9, NL-1105 AZ Amsterdam, The Netherlands. Phone: 31-20-5665910; Fax: 31-20-6977192; E-mail: m.p.peppelenbosch@amc.uva.nl

instance, bronchial constriction, vascular permeabilization, and synthesis of other inflammatory agents (4).

Exaggerated cellular histamine reactivity is associated with a variety of pathological conditions, in particular, asthmatic disease and other allergic disorders (5). The molecular details underlying the enhanced histamine reactivity remain obscure (6). Cells isolated from histamine hyperresponsive patients do not display exaggerated histamine responses *ex vivo*, and therefore factors present in the patient probably mediate hyperresponsiveness. Several possible mediators for histamine hyperreactivity have been described, including the cysteinyl leukotrienes (7,8). In 1983 Griffin (9) suggested that these inflammatory mediators are capable of inducing enhanced histamine reactivity. In agreement with this notion, it was demonstrated shortly afterward that cysteinyl leukotrienes cause fast and transient histamine hypersensitivity in guinea pig tracheal smooth muscle and airways (10,11) and that inhalation challenge with cysteinyl leukotrienes produces hyperreactivity to histamine in human subjects (12,13). Furthermore, we recently demonstrated that in F9 embryonic carcinoma cells, histamine responses are strongly enhanced by prior application of leukotriene D₄ (LTD₄) or leukotriene E₄ (LTE₄) (6). Therefore, cysteinyl leukotrienes appear to be capable of increasing histamine responsiveness both *in vitro* and *in vivo*, and *in vitro* stimulation of cells with these inflammatory lipids might provide a model system for studying histamine hyperreactivity.

These considerations prompted us to test the effect of cysteinyl leukotrienes on histamine responses of cells associated with histamine reactivity *in vivo*. Here we report that LTD₄ and LTE₄ enhance histamine-induced prostaglandin E₂ (PGE₂) production in immortalized mouse macrophages as well as in primary isolated human monocytes and human umbilical smooth muscle cells. This increase in histamine responsiveness coincided with an immediate and transient appearance of additional H₁ receptors on the plasma membrane as determined by Scatchard analysis. We conclude that stimulation of histamine responses by cysteinyl leukotrienes is a general phenomenon in cell types mediating histamine hyperreactivity in pathophysiology, and that this effect is probably mediated by a recruitment of additional H₁ receptors to the plasma membrane.

Materials and Methods

Chemicals

Histamine dihydrochloride, serotonin, pyrilamine (maleate salt), and lipopolysaccharide (LPS) from *E. coli* serotype 0111:B4 were obtained from Sigma (St. Louis, MO). Leukotrienes were from Cayman Chemical (Ann Arbor, MI), fetal calf serum (FCS) and DMEM/F12 medium were from Gibco BRL (Gaithersburg, MD), RPMI 1640 medium was from Biowhittaker (Walkersville, MD), and the prostaglandin E₂ biotrak EIA system and [pyridinyl-5-³H] pyrilamine were obtained from Amersham Life Science (Buckinghamshire, UK). Tumor necrosis factor α (TNF- α) and the murine macrophage 4/4 clone, isolated as described previously (14), were a kind gift from Professor Van Roy from the Department of Molecular Biology, University of Ghent.

Cell Culture

For routine culture, murine macrophages were grown in RPMI 1640 medium supplemented with 7.5% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 40 μ M β -mercaptoethanol (complete RPMI). The primary culture of human smooth muscle cells was grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 7.5% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin on gelatine-coated culture dishes. All incubations were carried out at 37°C under a humidified atmosphere of 95% air/5% CO₂. The cells were passaged two times a week using EDTA (0.2 mg/ml) for the macrophages and trypsin (0.05%)–EDTA (0.2 mg/ml) for the smooth muscle cells. The cells were plated on 24-well dishes 2 days before experimentation.

Isolation of Human Blood Monocytes

Blood was taken from six healthy volunteers and diluted 1:2 (v/v) with phosphate-buffered saline (PBS) solution. Peripheral blood mononuclear cells (PBMC) were isolated by centrifugation of diluted blood on a Ficoll gradient (1400 \times g, 20 min, 20°C). PBMC were washed twice with complete RPMI 1640 medium by centrifugation (600 \times g, 10 min, 20°C). Human monocytes were isolated by plating PBMC in 24-well dishes (2 \times 10⁵ cells/well). Following a 2-hr attachment period, the medium was removed by aspiration; monolayers were rinsed twice with fresh complete RPMI 1640 medium. Human monocytes

were used for PGE₂ determinations and for Scatchard analysis the next day.

PGE₂ Determinations

For PGE₂ determinations cells were maintained in serum-free medium for 3 hr and challenged with different stimuli, such as different concentrations of histamine, 100 ng/ml LTD₄ or LTE₄, 5% FCS, 50 ng/ml TNF- α , 10 μ g/ml LPS, and 10 μ M acetylcholine for 1 hr. Subsequently, the supernatant of the cells was collected and prostaglandin E₂ production was measured using a commercially available immunoassay (Amersham Life Science) according to the manufacturer's protocol.

[³H]-Pyrilamine Binding

Scatchard analysis was performed on intact cells as described earlier. For Scatchard analysis, cells were serum starved for 1 hr and where appropriate, stimulated with 100 ng/ml LTD₄ or LTE₄, 10% FCS, 1 μ M serotonin, 10 μ M acetylcholine, and 2 μ M bradykinin for different time intervals at 37°C. Subsequently, cells were labeled for 75 min at 4°C in PBS containing 4 nM [³H]-pyrilamine and 12 different concentrations of unlabeled pyrilamine. The reaction was stopped by washing the cells six times with ice-cold PBS and cells were lysed with 1% NP40 for at least 30 min. The bound radioactivity was determined by liquid scintillation counting. In each experiment each condition was performed in duplicate.

In general, Scatchard plots made in intact cells show considerable nonspecific low-affinity binding of [³H]-pyrilamine. Therefore, Scatchard plots were fitted according to a one- or two-site model, using the following formula:

$$\begin{aligned} \text{Bound/Free} = & 0.5\{[B_{\max 1} - \text{Bound}]/K_{d1} \\ & + [B_{\max 2} - \text{Bound}]/K_{d2}\} \\ & + 0.5\sqrt{\{[(B_{\max 1} - \text{Bound})/K_{d1} \\ & + (B_{\max 2} - \text{Bound})/K_{d2}]^2 \\ & + 4(B_{\max 1}B_{\max 2})/(K_{d1}K_{d2})\}} \end{aligned}$$

in which B_{max1}, B_{max2}, K_{d1}, and K_{d2} are the respective maximal binding capacities and dissociation constants of the different affinities. The observed points of the Scatchard plots of unstimulated cells were satisfactory fit with a one-site (low-affinity) model, while two affinity binding sites could be distinguished in the sensitized cells. To determine the best fit, we calculated the

χ^2 distribution of the estimated curve relative to the observed values. We accepted the fit if the χ^2 did not exceed the *p* value of 5%.

Results

Leukotrienes Induce Histamine Hyperresponsiveness In Vitro

The molecular mechanisms underlying histamine hyperresponsiveness are still poorly understood, partly as a consequence of the absence of an in vitro system for studying this process. Leukotrienes are capable of inducing histamine hypersensitivity in vivo. Recently, we showed that these inflammatory compounds augment histamine responses in certain embryo carcinoma cell lines (6). We decided, therefore, to test the effect of cysteinyl leukotrienes on cell types associated with histamine reactivity in vivo. For assaying histamine responses, we used the histamine-induced production of the inflammatory lipid PGE₂ as a functional measure (15). It appeared that histamine caused a small, but statistically significant, increase in PGE₂ production in primary isolated human umbilical smooth muscle cells (Fig. 1A), immortalized 4/4 murine macrophages (Fig. 1B), and freshly isolated human monocytes (Fig. 1C). In the latter cell type, however, high histamine concentrations were not as effective as lower concentrations in stimulating PGE₂ production. Addition of 100 ng/ml LTD₄ or LTE₄ to these cell types was also capable of inducing a modest, but statistically significant, stimulation of PGE₂ synthesis highly comparable to that observed with histamine. Addition of either LTD₄ or LTE₄ together with histamine, however, strongly enhanced prostaglandin E₂ release in both smooth muscle cells and macrophages, as well as monocytes (Fig. 1A–C). We concluded that cysteinyl leukotrienes are capable of increasing histamine responsiveness in vitro in cell types relevant for histamine hypersensitivity in vivo.

Histamine Hyperresponsiveness Induced by Fetal Calf Serum

To further characterize the induction of histamine responsiveness, we investigated whether the histamine hyperresponsiveness was restricted to leukotrienes or can be mediated by a broader spectrum of inflammatory stimuli. We stimulated human smooth muscle cells and murine 4/4 macrophages with a variety of inflammatory stimuli, including 50 ng/ml TNF- α , 10




Fig. 1. Effects of cysteinyl leukotrienes on histamine hyperresponsivity in human umbilical smooth muscle cells (A), immortalized 4/4 murine macrophages (B), and freshly isolated human monocytes (C). Cells were stimulated with different concentrations of histamine in the absence (open circles) or presence (filled circles) of 100 ng/ml LTD₄ (A) or 100 ng/ml LTE₄ (B,C) for 1 hr. The histamine-induced PGE₂ production was used as a functional measure to determine the histamine responses in these cells. Results represent the mean and standard error of four independent experiments. Statistically significant differences were calculated using the *t*-test; **p* < 0.05 and ***p* < 0.01.

μg/ml LPS, and 10 μM acetylcholine and 5% FCS, in the presence or absence of histamine. Neither TNF-α, LPS, nor acetylcholine enhanced histamine-induced PGE₂ synthesis (data not shown). In contrast, FCS was capable of stimulating histamine-induced PGE₂ production in smooth muscle cells (Fig. 2). Although application of FCS alone induced increased PGE₂ release compared to unstimulated cells, co-application of histamine and FCS had a strong synergistic effect (Fig. 2). Apparently, induction of enhanced histamine responsiveness is not a general consequence of inflammatory stimulation but a specific reaction to a subset of different stimuli.

Leukotrienes Cause an Immediate Appearance of Additional H₁ Receptors on the Plasma Membrane

Induction of increased histamine responses in vitro seems to be associated with an upward shift of the histamine dose-response curve, instead of a shift to the left (Fig. 1). This suggests that induction of histamine responses involves either an appearance of more histamine receptors on the plasma membrane or a more efficient signaling per receptor and not an increase in receptor affinity. We decided to test the effect of leukotrienes in Scatchard analysis, which allows deter-




Fig. 2. Effects of FCS on histamine hyperresponsivity in human umbilical smooth muscle cells. Cells were stimulated with different concentrations of histamine in the absence (open circles) or presence (filled circles) of 5% FCS for 1 hr. The histamine-induced PGE₂ production was used as a functional measure to determine the histamine responses in these cells. Results represent the mean and standard error of three independent experiments. Statistically significant differences were calculated using the *t*-test; ***p* < 0.01.

mination of both histamine receptor affinity as well as the receptor number. Unfortunately, we were not able to culture primary isolated umbil-

Table 1. Effects of leukotriene E₄ on number of histamine H₁ receptors in human peripheral blood monocytes

Volunteer	Receptors/ cell before stimulation	Receptors/ cell after stimulation	K _d (nM)
A	54207	105403	6
B	45173	90345	6
C	22586	48184	5.5
D	12046	57219	6.7
E	2259	9787	3

Blood was isolated from five healthy volunteers (A–E) and monocytes were prepared. These cells were stimulated with leukotriene E₄ (100 ng/ml) for 15 min. Scatchard analysis was performed to determine number of receptors per cell as described in Materials and Methods.

ical smooth muscle cells in sufficient amounts to allow Scatchard analysis, but in both murine macrophages as well as primary isolated human monocytes histamine receptors are readily detected. Using [³H]-mepyramine as a probe (which has an approximately 1000-fold higher affinity for the histamine H₁ receptor than histamine itself), we observed in these cells histamine receptors exhibiting an apparent K_d value of 3–6 nM for mepyramine, which is well in line with the reported values of this receptor (6) (Table 1, Figs. 3 and 4). LTE₄ stimulation did not affect the affinity of these histamine H₁ receptors, but strongly enhanced the number of histamine receptors in both human monocytes isolated from five different healthy volunteers as well as in 4/4 mouse macrophages. This effect was specific to cysteinyl leukotrienes: using Scatchard analysis we tested the effect of adding different inflammatory stimuli to macrophages on histamine receptor number, including LTD₄, bradykinin, acetylcholine, and serotonin, and only LTD₄ mimicked the effect of LTE₄ (not shown). We propose, therefore, that a leukotriene-dependent increase in receptor number underlies the leukotriene-induced increase in PGE₂ production.

Temporal Kinetics of Histamine Receptor Induction

To further characterize the leukotriene-induced increase in histamine receptors, we investigated the time-dependency of this effect. As depicted in Figures 5 and 6, in both murine macrophages




Fig. 3. Effects of leukotriene E₄ on number of histamine H₁ receptors in murine macrophages. The Scatchard plot represents the binding of [³H]-pyrilamine to murine macrophages, left unstimulated (open circles) or stimulated (filled circles) with LTE₄ (100 ng/ml) for 10 min. Scatchard analysis was performed to determine number of receptors per cell as described in Materials and Methods. We measured 1.9×10^5 receptors/cell before stimulation and 4×10^5 receptors/cell after stimulation with a K_d value of 5.5 nM.

as well as primary isolated human monocytes, a 5-min incubation with LTE₄ already produces a strong increase in histamine receptor number. In mouse macrophages, at later time points even more histamine receptors were detected, a maximum effect being reached at 15 min, after which receptor numbers declined again, although an increase above the control level was still detected 1 hr post-stimulation (Fig. 5). In human monocytes, maximal induction of histamine receptors was observed 5 min after application of LTE₄, whereas at later time points, the number of receptors gradually declined (Fig. 6). These results demonstrate, therefore, that the cysteinyl leukotriene-induced increase in histamine H₁ receptor number is extremely fast, and of a transient nature.

Discussion

Histamine reactivity is under dynamic control and exaggerated histamine responses have been implicated in a variety of pathological conditions. The molecular mechanisms regulating histamine responsiveness are poorly understood. Strikingly, cells isolated from patients exhibiting clinical histamine hyperreactivity do not display such histamine hyperreactivity in vitro (16–19), demonstrating that factors present in the patient




Fig. 4. Effects of leukotriene E_4 on number of histamine H_1 receptors in human peripheral blood monocytes. Blood was isolated from four healthy volunteers (A–D) and monocytes were prepared. The following day, monocytes were either left unstimulated (open circles) or stimulated with leukotriene E_4 (100 ng/ml) (filled circles) for 15 min. Scatchard analysis was performed to determine number of receptors per cell as described in Materials and Methods.

are essential for histamine hyperresponsiveness. These factors have not yet been conclusively identified, but may include cysteinyl leukotrienes, as these inflammatory lipids enhance histamine reactivity in human subjects in vivo (9,12,13,20,21). Recently, we demonstrated that such cysteinyl leukotrienes enhance histamine responses in certain embryo carcinoma cell lines (6). We decided to investigate, therefore, whether cysteinyl leukotrienes are able to increase histamine responses in cell types important in histamine reactivity in vivo. We observed that in vitro stimulation with these inflammatory lipids strongly enhanced the cellular reaction to histamine in primary isolated umbilical smooth muscle cells, in a murine macrophage cell line, and in human monocytes. Therefore, cysteinyl leukotrienes are direct regulators of histamine responsiveness *ex vivo*.

Our experimental system allowed us to investigate the mechanisms underlying histamine hyperresponsiveness in vitro. We employed PGE_2 production as a measure for histamine responses, which was determined 1 hr after stimulation. This time frame indicates that induction of enhanced histamine responsiveness by cysteinyl leukotrienes is protein synthesis indepen-




Fig. 5. Transient nature of histamine receptor induction in murine macrophages. Macrophages were stimulated with LTE_4 for different time intervals and Scatchard analysis was performed to determine number of receptors per cell as described in Materials and Methods.

dent, in agreement with in vivo results (12). This leaves three different possibilities of explaining the induction of increased histamine responses:




Fig. 6. Transient nature of histamine receptor induction in human blood monocytes. Blood was taken from one volunteer (E in Table 1) and monocytes were isolated. The following day, the cells were either left unstimulated (open circles) or stimulated with LTE₄ (100 ng/ml) for 5 min (A), 15 min (B) or 30 min (C) (filled circles). (D) Amount of histamine H₁ receptors at the indicated time intervals. Scatchard analysis was performed to determine number of receptors per cell as described in Materials and Methods.

first, cysteinyl leukotrienes may increase the affinity of the histamine receptor for its ligand, second, leukotrienes may induce increased signal transduction per receptor, and third, leukotrienes may unmask histamine receptors already present but unable to interact with their ligands. The dose-response relationship of the histamine-induced prostaglandin synthesis does not display a leftward shift on Scatchard analysis after stimulation with cysteinyl leukotrienes, which is apparently in disagreement with a leukotriene-induced increase in histamine receptor affinity. Scatchard analysis did not reveal differences in histamine receptor affinity before or after stimulation of histamine responsiveness, but it did show an increase in receptor number after addition of leukotrienes to either primary isolated monocytes or mouse macrophages; this increase appears to correlate with enhanced histamine-induced prostaglandin production. We propose, therefore, that cysteinyl leukotrienes may induce histamine hyperreactivity *in vitro* by unmasking histamine receptors that were previously unable to bind their ligand.

The molecular details by which cysteinyl leukotrienes may produce such an unmasking of histamine receptors remain unclear. In general, receptors may be continuously recycled between the plasma membrane and the endosomes. Therefore, a pool of histamine receptors may

exist that is physically unable to bind its ligand, due to an endosomal localization. As it is now becoming clear that many external stimuli may profoundly influence vesicular trafficking, it is conceivable that cysteinyl leukotrienes mobilize such an endosomal pool of histamine receptors to produce an increased number of receptors on the plasma membrane and enhanced histamine responsiveness. Alternatively, a pool of histamine receptors unable to bind their ligand may exist on the plasma membrane. Addition of leukotriene may induce a conformational change in these histamine receptors already present on the plasma membrane, to allow ligand binding. Obviously, further experimental work is required to discern between these possibilities.

A dynamic regulation of histamine responsiveness is further supported by the transient nature of the effects observed. Both in macrophages and primary isolated human monocytes, maximal numbers of histamine receptors are observed within 5–15 min after stimulation with cysteinyl leukotrienes, and clearly decline again within an hour. This corresponds well with the timing of kinetics of the leukotriene-induced histamine hyperreactivity in guinea pig tracheal smooth muscle observed by Lee et al. (10), who observed maximal stimulation of histamine-induced contraction 10 to 15 min after application of cysteinyl leukotriene and a return to unstimu-

lated histamine responsiveness within 30 min. Studies performed in vivo, however, have shown much longer durations of cysteinyl leukotriene histamine hyperresponsiveness (13), therefore, the effects observed in the present study cannot be directly extrapolated to the asthmatic patient. As histamine receptor activation is in itself a potent inducer of leukotriene synthesis, positive feedback may partly explain the discrepancy between the effects observed in vitro and in vivo. Furthermore, in vivo production of other secondary mediators (cytokines, interleukins, etc.) clearly influences histamine hyperreactivity (15). Therefore, studies investigating cysteinyl leukotriene-induced histamine receptor unmasking in cells obtained in patients suffering from histamine hypersensitivity are needed to establish whether the enhancement of histamine receptor numbers observed in vitro may also be relevant in pathophysiology. Studies addressing this problem are currently in progress.

Acknowledgments

The authors thank our volunteers for their cooperation and the other members of our laboratories for stimulating discussions.

References

1. Werle E, Lorenz W. (1966) Histamine and histidine decarboxylases in the thyroid and the thymus. *Biochem. Pharmacol.* **15**: 1059–1070.
2. Kahlson G, Rosengren E. (1968) New approaches to the physiology of histamine. *Physiol. Rev.* **48**: 155–196.
3. Hill SJ, Ganellin CR, Timmerman H, et al. (1997) Classification of histamine receptors. *Pharmacol. Rev.* **49**: 253–278.
4. Hill SJ. (1990) Distribution properties and functional characteristics of three classes of histamine receptors. *Pharmacol. Rev.* **42**: 45–83.
5. Barnes PJ, Chung KF, Page CP. (1998) Inflammatory mediators of asthma: an update. *Pharmacol. Rev.* **50**: 515–596.
6. Bloemers SM, Verheule S, Peppelenbosch MP, Smit MJ, Tertoolen LG, de Laat S. (1998) Sensitization of the histamine H1 receptor by increased ligand affinity. *J. Biol. Chem.* **273**: 2249–2255.
7. Busse WW. (1998) Leukotrienes and inflammation. *Am. J. Respir. Crit. Care Med.* **157**: S210–S213.
8. Thien FC, Walters EH. (1995) Eicosanoids and asthma: an update. *Prostaglandins Leukot Essent Fatty Acids* **52**: 271–288.
9. Griffin M, Weiss JW, Leitch AG, et al. (1983) Effects of leukotriene D on the airways of asthma. *N. Engl. J. Med.* **308**: 436–439.
10. Lee TH, Austen KF, Corey EJ, Drazen JM. (1984) Leukotriene E4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. *Proc. Natl. Acad. Sci. U.S.A.* **81**: 4922–4925.
11. Kurosawa M, Tsukagoshi H. (1993) Inhibitory effect of a thromboxane A2 synthetase inhibitor OKY-046 on bronchial hyperresponsiveness to histamine, but not on airway wall thickening, induced by intravenous administration of leukotriene C4 in guinea-pigs. *Pulm. Pharmacol.* **6**: 247–253.
12. Arm JP, Spur BW, Lee TH. (1988) The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. *J. Allergy Clin. Immunol.* **82**: 654–660.
13. O'Hickey SP, Hawsworth RJ, Fong CY, Arm JP, Spur BW, Lee TH. (1991) Leukotrienes C4, D4 and E4 enhance histamine responsiveness in asthmatic airways. *Am. Rev. Respir. Dis.* **144**: 1053–1057.
14. Desmedt M, Rottiers P, Dooms H, Fiers W, Grooten J. (1998) Macrophages induce cellular immunity by activating Th1 cell responses and suppressing Th2 cell responses. *J. Immunol.* **160**: 5300–5308.
15. Barnes PJ (1991) Biochemistry of asthma. *Trends Biochem. Sci.* **16**: 365–369.
16. Fukushima C, Shimoda T, Matsuse H, et al. (1999) In vitro responses to antigen stimulation: comparison between human lung parenchyma resected from asthmatic patients and non-asthmatic patients. *Ann. Allergy Asthma Immunol.* **82**: 179–184.
17. Bjorck T, Gustafsson LE, Dahlen SE. (1992) Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. *Am. Rev. Respir. Dis.* **145**: 1087–1091.
18. Meurs H, Koeter GH, Kauffman HF, Timmermans A, Folkers B, de Vries K. (1985) Reduced adenylyl cyclase responsiveness to histamine in lymphocyte membranes of allergic asthmatic patients after allergen challenge. *Int. Arch. Allergy Appl. Immunol.* **76**: 256–260.
19. Goldie RG, Spina D, Henry PJ, Lulich KM, Paterson JW (1986) In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline. *Br. J. Clin. Pharmacol.* **22**: 669–676.
20. Kern R, Smith LJ, Patterson R, Krell RD, Bernstein PR. (1986) Characterization of the airway response to inhaled leukotriene D4 in normal subjects. *Am. Rev. Respir. Dis.* **133**: 1127–1132.
21. Kaye MG, Smith LJ. (1990) Effects of inhaled leukotriene D4 and platelet-activating factor on airway reactivity in normal subjects. *Am. Rev. Respir. Dis.* **141**: 993–997.